Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.41 |
| ▸ | WNT3A | P56704 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712527 | 1.00 | LMNA (0.50) | LMNAGAACNR2PTGS1CTNNB1 | |
| Hydrochloric Acid SCHEMBL3065338 | 0.98 | LMNA (0.48) | LMNAGAACNR2PTGS1CTNNB1 | |
| Hydrochloric Acid SCHEMBL31138645 | 0.98 | LMNA (0.48) | LMNAGAACNR2PTGS1CTNNB1 | |
| Hydrochloric Acid SCHEMBL1259553 | 0.96 | LMNA (0.47) | LMNAGAACNR2PTGS1CTNNB1 | |
| SCHEMBL17558530 | 0.84 | PARP1 (0.43) | LMNAGAAALDH1A1TDP1GRIN2D | |
| SCHEMBL6208835 | 0.82 | LMNA (0.38) | LMNAGAAPTGS1ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL27788451 | 0.80 | LMNA (0.37) | LMNAGAAPTGS1ALDH1A1POLB | |
| SCHEMBL6145627 | 0.78 | LMNA (0.50) | LMNAGAACNR2PTGS1CTNNB1 | |
| SCHEMBL118007 | 0.78 | LMNA (0.60) | LMNAGAACNR2PTGS1CTNNB1 | |
| SCHEMBL20476361 | 0.78 | TDP1 (0.46) | ALDH1A1TDP1GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146971-A1 | NOVEL BENZAMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-01-27 | — | — | EP | claimed |
| WO-2008135591-A1 | NOVEL BENZAMIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | WO | claimed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| US-12570638-B2 | Fused imidazole derivatives as AHR antagonists | SAIL BIOMEDICINES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20240150506-A1 | CURING AGENTS FOR FLUOROELASTOMERS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2024-05-09 | — | — | US | disclosed |
| CN-117529520-A | Fluoroelastomer compositions containing curative | 杜邦特种产品美国有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4305096-A1 | FLUOROELASTOMERS COMPOSITION COMPRISING CURING AGENTS | Dupont Specialty Products USA, LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | SENDA BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | SENDA BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | SENDA BIOSCIENCES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-7041685-B2 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | disclosed |
| EP-1532145-A1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | disclosed |
| WO-2004013140-A1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-3867448-A | Trifluoromethylphenyl-formamadines and acetamidines | CIBA GEIGY AG | 1975-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | LMNA 3388/4885GAA 1592/4885CNR2 275/4885 |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | LMNA 1419/4885GAA 3175/4885CNR2 2583/4885 |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | GSK3A, GSK3B, GSKIP | LMNA 1062/4885GAA 1592/4885CNR2 4599/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LMNA 1950/4885GAA 3050/4885CNR2 71/4885 |
| US-20230331705-A1 | Fused Imidazole Derivatives as AHR Antagonists | AHR, ARNT, AIPL1 | LMNA 4539/4885GAA 3368/4885CNR2 342/4885 |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP4 | LMNA 1844/4885GAA 3337/4885CNR2 2936/4885 |
| US-12570638-B2 | Fused imidazole derivatives as AHR antagonists | AHR, ARNT, AIPL1 | LMNA 3352/4885GAA 4320/4885CNR2 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.